ResMed: GLP-1 Threats Are Overstated

ResMed is described as trading below its fundamentals despite double-digit top-line growth and margins that are said to far exceed peers. The article argues GLP-1-related share loss fears are overstated, with remaining demand potentially more profitable, though PHG's reentry and Apnimed's drug commercialization are cited as competitive risks. Overall, the view is that RMD should retain market dominance.

Analysis

The market is still pricing RMD as if GLP-1s are a category-level substitute for PAP therapy, but that framing misses the more important second-order effect: the installed base that remains is likely higher quality. If lower-acuity patients peel off first, RMD’s mix should skew toward more adherent, more severe, and higher-LTV users, which supports recurring revenue quality and gross margin durability even if unit growth moderates. In other words, share loss can coexist with a better economic profile per remaining patient.

The bigger competitive risk is not GLP-1 headline risk; it is distribution and reimbursement friction if competitors use drug-driven narratives to pressure prescribing behavior or payer formularies. PHG’s reentry matters mainly if it forces channel incentives to reset, while Apnimed is a longer-duration threat because oral commercialization could re-open the market one step earlier in the treatment funnel. But those are multi-quarter to multi-year risks, and the stock appears to be discounting an immediate deterioration that is not yet visible in the operating data.

The contrarian setup is that the multiple is already reflecting a negative earnings revision cycle, so any evidence of sustained double-digit top-line growth or margin resilience should compress the risk premium quickly. The likely catalyst path is sequential: next quarterly print, then commentary on payer behavior, and finally any proof that GLP-1 adoption is reducing low-value demand without impairing core therapy adoption. If that pattern holds, the market may have to re-rate RMD as a premium-quality durable compounder rather than a threatened med-tech incumbent.

Key Decisions for Investors

• Go long RMD on pullbacks over the next 2-6 weeks; target a 10-15% re-rating if the next print confirms revenue growth and margin stability, with downside limited to multiple compression only if management guides to meaningful volume deceleration.
• Use a call spread in RMD (3-6 months expiry) to express the view that consensus is underestimating margin durability; risk/reward is favorable if the stock re-rates on even modestly positive guidance.
• Pair trade: long RMD / short a basket of slower-growth sleep/respiratory med-tech names where margin quality is lower; this isolates the thesis that RMD’s remaining demand is higher quality and more defensible.
• If you want event-driven exposure, add after the next earnings release only if management confirms no payer-driven deterioration; this reduces the risk of paying for a narrative before the market sees operating proof.